5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

Peritoneal Cancer ◽

Blind Trial ◽

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.09.015 ◽

2019 ◽

Vol 155 (3) ◽

pp. 393-399 ◽

Cited By ~ 4

Author(s):

Roisin E. O’Cearbhaill ◽

Wei Deng ◽

Lee-may Chen ◽

Joseph A. Lucci ◽

Kian Behbakht ◽

...

Keyword(s):

Complete Remission ◽

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Peritoneal Cancer ◽

Blind Trial ◽

Polyvalent Vaccine

A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.

10.1200/jco.2016.34.15_suppl.5517 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5517-5517

Author(s):

Paul Sabbatini ◽

Lee-may Chen ◽

Joseph A. Lucci ◽

Kian Behbakht ◽

Nicola M. Spirtos ◽

...

Keyword(s):

Complete Remission ◽

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Peritoneal Cancer ◽

Blind Trial ◽

Polyvalent Vaccine

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

10.1200/jco.2015.33.15_suppl.5580 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5580-5580

Author(s):

John Ben Liao ◽

Ron E. Swensen ◽

Jessica Reichow ◽

Kelsie J Ovenell ◽

Jennifer Childs ◽

...

Keyword(s):

Immune Responses ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Immune Modulator ◽

Gm Csf ◽

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.03.036 ◽

2011 ◽

Vol 122 (1) ◽

pp. 111-115 ◽

Cited By ~ 57

Author(s):

Robert L. Coleman ◽

William E. Brady ◽

D. Scott McMeekin ◽

Peter G. Rose ◽

John T. Soper ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

10.1200/jco.2014.32.15_suppl.5585 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5585-5585 ◽

Cited By ~ 2

Author(s):

Kristen Paige Bunch ◽

Anne M. Noonan ◽

Jung-min Lee ◽

Ciara Catherine Maria O'Sullivan ◽

Nicole D. Houston ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Pharmacodynamic Biomarkers

Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

10.1200/jco.2018.36.15_suppl.5567 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Pierre Combe ◽

Isabelle Laure Ray-Coquard ◽

Florence Joly ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase Ii ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

10.1136/ijgc-2020-igcs.14 ◽

2020 ◽

Author(s):

N Nishikawa ◽

T Shoji ◽

T Enomoto ◽

M Abe ◽

A Okamoto ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Standard Of Care ◽

Efficacy And Safety ◽

Peritoneal Cancer ◽